🇺🇸 FDA

Intelligence Platform

Patents

Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11660318

Use of adipose tissue-derived stromal stem cells in treating fistula

Takeda Pharmaceutical Company Limited · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11660325

Compositions and methods of targeting cancer stem cells

The Board of Regents of the University of Texas System · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642401

Activation of resident memory T cells for cancer immunotherapy

Regents of the University of Minnesota · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11629334

Methods of isolating T cells and T cell receptors having antigenic specificity for a cance

THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11631483

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11622977

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11613754

Toxic RNAi active seed sequences for killing cancer cells

Northwestern University · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11613735

Methods for reprograming non-hepatocyte cells into hepatocyte cells

BeiHao Stem Cell and Regenerative Medicine Translational Research Institute · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11613739

Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) p

REGENXBIO INC. · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11591381

Gene-edited natural killer cells

CRISPR THERAPEUTICS AG · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11591622

Method of making and using mammalian liver cells for treating hemophilia or lysosomal stor

Sangamo Therapeutics, Inc. · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11583556

Modified cells and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11583557

Placenta-derived multipotent stem cells

The Regents of the University of California · Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11578309

Universal donor cells

CRISPR THERAPEUTICS AG · Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11571445

Genetically engineered hematopoietic stem cells and uses thereof

Vor Biopharma Inc. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11572541

Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treat

Providence Health & Services—Oregon · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566242

Methods and compositions for reprogramming cells

The Regents of the University of Colorado, a Body Corporate · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566230

Universal donor cells

CRISPR THERAPEUTICS AG · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566228

Hemangio-colony forming cells

Astellas Institute for Regenerative Medicine · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559551

Genetically engineered hematopoietic stem cells and uses thereof

Vor Biopharma Inc. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11555057

Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor

The Regents of the University of California · Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504402

Compositions comprising bacterially derived minicells and methods of using the same

EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497773

Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485976

Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same

EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted